- Home
- PKE vs AVIR Comparison
PKE vs AVIR Comparison
Compare PKE & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- AVIR
- Stock Information
- Founded
- PKE 1954
- AVIR 2012
- Country
- PKE United States
- AVIR United States
- Employees
- PKE N/A
- AVIR N/A
- Industry
- PKE Military/Government/Technical
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- PKE Industrials
- AVIR Health Care
- Exchange
- PKE Nasdaq
- AVIR Nasdaq
- Market Cap
- PKE 378.7M
- AVIR 290.4M
- IPO Year
- PKE N/A
- AVIR 2020
- Fundamental
- Price
- PKE $19.01
- AVIR $2.91
- Analyst Decision
- PKE
- AVIR Hold
- Analyst Count
- PKE 0
- AVIR 1
- Target Price
- PKE N/A
- AVIR $6.00
- AVG Volume (30 Days)
- PKE 91.9K
- AVIR 217.7K
- Earning Date
- PKE 10-14-2025
- AVIR 11-06-2025
- Dividend Yield
- PKE 2.60%
- AVIR N/A
- EPS Growth
- PKE 4.18
- AVIR N/A
- EPS
- PKE 0.34
- AVIR N/A
- Revenue
- PKE $63,456,000.00
- AVIR N/A
- Revenue This Year
- PKE N/A
- AVIR N/A
- Revenue Next Year
- PKE N/A
- AVIR N/A
- P/E Ratio
- PKE $55.95
- AVIR N/A
- Revenue Growth
- PKE 16.60
- AVIR N/A
- 52 Week Low
- PKE $11.97
- AVIR $2.46
- 52 Week High
- PKE $20.73
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- PKE 56.02
- AVIR 29.44
- Support Level
- PKE $18.19
- AVIR $3.10
- Resistance Level
- PKE $19.31
- AVIR $3.33
- Average True Range (ATR)
- PKE 0.67
- AVIR 0.14
- MACD
- PKE -0.06
- AVIR -0.05
- Stochastic Oscillator
- PKE 57.75
- AVIR 7.69
About PKE Park Aerospace Corp.
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).